{"entity":{"id":"idea-reg-hospital-exemption-harmonised","kind":"idea","name":"Harmonise Europe's hospital exemption for academic cell therapies, with one registry","aka":[],"tldr":"Spain lets hospitals make and use their own CAR-T under a special rule; most European countries do not. A common rule with shared outcome tracking would spread affordable academic products.","summary":"The EU ATMP Regulation's hospital exemption is implemented differently in each member state: Spain has authorised academic CAR-T products (ARI-0001, ARI-0002h) at far lower cost than commercial products, while other countries apply the exemption so narrowly that academic products cannot be used routinely. The 2023 EU pharmaceutical reform proposals address this partly. The proposal is a harmonised hospital exemption with common GMP and pharmacovigilance requirements, mandatory participation in a European outcomes registry, and cross-border recognition so an exempted product from one member state can be used in another.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"}],"tags":[],"related":[],"cancers":["all-leukemia","multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-regulatory-fragmentation"],"keyPapers":["paper-hernandez-jama-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Harmonisation increases the number of European patients treated with academic CAR-T tenfold within five years, with 12-month outcomes within the range of commercial products in the same registry.","rationale":"Academic CAR-T has published outcomes comparable to commercial products in matched populations at a third of the price; the barrier is legal fragmentation, not quality.","test":"Compare registry outcomes for academic and commercial CAR-T in Spain; model the access gain from harmonisation; pilot cross-border use between two member states under a bilateral agreement.","maturity":"early-clinical","actor":"policy","cost":"small","horizonYears":4},"route":"/ideas/idea-reg-hospital-exemption-harmonised/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"}],"paper":[{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/"}]}}